Evidence map›Paper›PMID 36893711›Full record

Trial reportEuropean journal of cancer (Oxford, England : 1990)2023

OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.

Mark E Robson, Seock-Ah Im, Elzbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Nadine Tung, Anne Armstrong, Mike Dymond and 3 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of cancer (Oxford, England : 1990), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 6 pooled it
21.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 6 syntheses or guidelines pooled it, 97 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Prognostic implications of tissue-based homologous recombination deficiency in metastatic gastric cancer treated with immune checkpoint inhibitor plus chemotherapy.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 12 institutions in 8 countries.

Mark E RobsonMemorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: robsonm@mskcc.org.
Seock-Ah ImSeoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
Elzbieta SenkusMedical University of Gdańsk, Gdańsk, Poland.
Binghe XuCancer Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Susan M DomchekBasser Centre, University of Pennsylvania, Philadelphia, PA, USA.
Norikazu MasudaNagoya University Graduate School of Medicine, Nagoya, Japan.
Suzette DelalogeInstitut Gustave Roussy, Villejuif, France.
Nadine TungBeth Israel Deaconess Medical Center, Dana-Farber Harvard Cancer Center, Boston, MA, USA.
Anne ArmstrongThe Christie NHS Foundation Trust, Manchester, UK.
Mike DymondAstraZeneca, Cambridge, UK.
Anitra FieldingAstraZeneca, Gaithersburg, MD, USA.
Allison AllenAstraZeneca, Gaithersburg, MD, USA.
Pierfranco ConteDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Medical Oncology 2, University of Padova and Istituto Oncologico Veneto IRCCS, Padova, Italy.
AstraZeneca (United States) · USAstraZeneca (United Kingdom) · GBBeth Israel Deaconess Medical Center · USChinese Academy of Medical Sciences & Peking Union Medical College · CNGdańsk Medical University · PLInstitut Gustave Roussy · FRMemorial Sloan Kettering Cancer Center · USNagoya University · JPSeoul National University Hospital · KRThe Christie NHS Foundation Trust · GBUniversity of Padua · ITUniversity of Pennsylvania · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundIn the Phase III OlympiAD study, olaparib significantly prolonged progression-free survival versus chemotherapy treatment of physician's choice (TPC) in patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2-negative metastatic breast cancer (mBC). In the final pre-specified analysis (64% maturity), median overall survival (OS) was 19.3 months for olaparib and 17.1 months for TPC (P = 0.513). Post-hoc extended follow-up, 25.7 months longer than previously reported for OS, is reported. PATIENTS AND

methodsPatients with gBRCAm, human epidermal growth factor receptor 2-negative mBC, who had received ≤2 lines of chemotherapy for metastatic disease, were randomised 2:1 to olaparib (300 mg bid) or TPC. During extended follow-up, OS was analysed every 6 months using the stratified log-rank test (overall population) and Cox proportional hazards model (pre-specified subgroups).

resultsIn the overall population (302 patients; 76.8% maturity), median OS was 19.3 months for olaparib and 17.1 months for TPC (hazard ratio 0.89, 95% confidence interval 0.67-1.18); median follow-up was 18.9 and 15.5 months, respectively. Three-year survival was 27.9% for olaparib versus 21.2% for TPC. With olaparib, 8.8% of patients received study treatment for ≥3 years versus none with TPC. In first-line mBC, median OS was longer for olaparib than TPC (22.6 versus 14.7 months; hazard ratio 0.55, 95% confidence interval 0.33-0.95) and 3-year survival was 40.8% for olaparib versus 12.8% for TPC. No new serious adverse events related to olaparib were observed.

conclusionsOS was consistent with previous analyses from OlympiAD. These findings support the possibility of meaningful long-term survival benefit with olaparib, particularly in first-line mBC.

Indexed as

Breast NeoplasmsPhysiciansErb-b2 Receptor Tyrosine KinasesFemaleFollow-Up StudiesGenes, BRCA1Genes, BRCA2Germ-Line MutationHumansPhthalazinesPiperazinesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesolaparibPhthalazinesPiperazinesBreast cancerGermline BRCA mutationOlaparibOverall survivalPARP inhibitor

Identifiers

PMID36893711
PMCPMC10585240
OpenAlexW4320717500

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.